Related Experiment Video

Updated: Jun 30, 2026

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

Late congestive heart failure after hematopoietic cell transplantation

Saro H Armenian1, Can-Lan Sun, Liton Francisco

  • 1Division of Hematology/Oncology, Childrens Hospital Los Angeles, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|September 24, 2008
PubMed

Insights

Pre-transplant chemotherapy and comorbidities significantly increase late congestive heart failure risk after hematopoietic cell transplantation (HCT). Conditioning therapy plays a minor role, highlighting the need for targeted surveillance and comorbidity management.

Area of Science:

  • Hematology
  • Oncology
  • Cardiology

Background:

  • Late congestive heart failure (CHF) is a serious complication following hematopoietic cell transplantation (HCT).
  • Identifying risk factors for late CHF is crucial for patient management and outcomes.

Purpose of the Study:

  • To investigate the independent contributions of pre-HCT therapeutic exposures, conditioning regimens, and comorbidities to the development of late CHF post-HCT.

Main Methods:

  • A nested case-control study was conducted using a cohort of 2,938 1+ year survivors of HCT.
  • Sixty patients with late CHF (diagnosed >= 1 year post-HCT) were matched with controls without CHF.

Main Results:

  • Patients who developed late CHF received more pre-HCT chemotherapy cycles, had higher lifetime anthracycline exposure, and were more likely to have multiple comorbidities.
  • Multivariable analysis identified pre-HCT chemotherapy cycles, anthracycline dose (>= 250 mg/m2), and multiple comorbidities as independent predictors of late CHF.

Conclusions:

  • Pre-HCT anthracycline exposure and pre-existing comorbidities are primary drivers of late CHF risk after HCT.
  • Transplantation conditioning regimens do not significantly contribute to late CHF risk.
  • Findings support targeted surveillance and aggressive comorbidity management for high-risk HCT survivors.
Abstract

More Related Videos

Murine Heterotopic Heart Transplant Technique10:27

Murine Heterotopic Heart Transplant Technique

Published on: July 8, 2014

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...